Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Closed Research Teams
  • View item
  • Home
  • ICR Divisions
  • Closed Research Teams
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer

Thumbnail
View/Open
Published version (1.082Mb)
Date
2013-01-15
ICR Author
Cooper, Colin
Author
Ahmad, I
Singh, LB
Yang, ZH
Kalna, G
Fleming, J
Fisher, G
Cooper, C
Cuzick, J
Berney, DM
Moller, H
Scardino, P
Leung, HY
Grp, TP
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Background: Aberrant mitogen/extracellular signal-regulated kinase 5 (MEK5)-extracellular signal-regulated protein kinase 5 (ERK5)-mediated signalling has been implicated in a number of tumour types including prostate cancer (CaP). The mechanism for ERK5 activation in CaP remains to be fully elucidated. Studies have recently implicated the role of microRNA (miRNA) mir143 expression in the regulation of ERK5 expression. Methods: We utilised a tissue microarray (TMA) of 530 CaP cores from 168 individual patients and stained for both mir143 and ERK5. These TMAs were scored by a combination of observer and automated methods. Results: We observed a strong inverse relation between ERK5 and mir143, which manifested itself most strongly in the subgroup of 417 cores with non-zero mir143 and ERK5 immunoreactivity, or with only one of mir143 or ERK5 being zero (cc = 0.2558 and P<0.0001). Mir143 neither correlate with Gleason scores or prostate-specific antigen levels, nor was it a predictor of disease-specific survival on univariate analysis. Conclusion: Although the mechanism for ERK5 activation in CaP remains to be fully elucidated, we have further validated the potential role of mir143 in regulating ERK5 levels in the clinical context. In addition, we demonstrate that the automated counting method for nuclear ERK5 is a clinically useful alterative to observer counting method in patient stratification in the context of ERK5 targeting therapy.
URI
https://repository.icr.ac.uk/handle/internal/2277
DOI
https://doi.org/10.1038/bjc.2012.510
Collections
  • Closed Research Teams
Research team
Cell Transformation
Language
eng
License start date
2013-01-15
Citation
BRITISH JOURNAL OF CANCER, 2013, 108 pp. 149 - 154
Publisher
NATURE PUBLISHING GROUP

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.